© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Poly(D,L-lactide-co-glycolide)—quite a mouthful, but for folks in medicine and materials science, these letters open the door to a biography of progress. Back in the 1970s, researchers looked at surgical sutures and saw a problem: the best ones stuck around too long, or broke down too fast, tearing tissue instead of supporting it. By dialing up combinations of lactic and glycolic acids, chemists unlocked a family of biodegradable polymers that could vanish once the body no longer needed them. RG 503 H, in particular, became more than a lab curiosity when tissue engineering and drug delivery took off in the 1980s and 1990s. I remember talking to old-guard biomedical engineers who admired how this stuff replaced bone pins for kids—no follow-up surgery, no infections from lingering foreign bodies. In many ways, RG 503 H didn’t just enter science; it helped set the stage for regenerative medicine’s launch.
Talking about RG 503 H these days means talking about an industry go-to. This copolymer isn’t obscure: you’ll spot it wherever dissolvable implants, micro-particle drug carriers, or experimental wound scaffolds come up. It shows up as a white, grainy powder or sometimes a translucent solid, almost nondescript if you didn’t know its role in saving lives. Unlike single-polymer devices, the lactide/glycolide blend offers tuning—change the ratio, and you can speed up or slow down how fast it disappears inside the body. That’s not academic; tailor-made formulations let surgeons, drug developers, and device manufacturers meet real problems head-on: slow antibiotic release to outsmart infections in bone fractures, or rapid breakdown for short-term tissue support in healing wounds.
Living with RG 503 H means dealing with a material that bridges two worlds: strong enough to provide a temporary skeleton, yet gentle enough for living tissue to wrap itself around. What strikes most newcomers is its glassy feel at room temperature and how it softens above body heat. The chain lengths—what chemists call molecular weight—land it somewhere between stretchy and brittle, which matters when microneedles, screws, or drug microparticles are extruded during manufacturing. Thanks to the lactide and glycolide mix in RG 503 H, the copolymer balances hydrophobicity with just enough water-loving sites for reliable breakdown. Both hydrolytic and enzymatic routes allow the body to metabolize it down to lactic and glycolic acid, which tie right into standard cellular energy cycles. That’s one reason the stuff earned broad safety acceptance: its metabolites don’t linger or threaten organs. Chemists can spot a typical fingerprint in its infrared or NMR spectrum, which helps ensure the absence of concerning contaminants batch after batch.
Manufacturers assign each batch rigorous identity numbers, monitoring attributes like molecular weight breakdown, residual monomers, and moisture. It’s easy for those unfamiliar to underestimate the importance of specification, but this is where a two-percent variance can mean a product’s success or failure. If degradation is too slow due to higher molecular weight, a wound scaffold overstays its welcome and can spark inflammation; too fast, and tissues aren’t supported long enough to heal. Technical certifications document everything from packaging to the absence of animal-derived components, which matters both ethically and for regulatory sign-off. Regulatory bodies set tight control over moisture content—excess water can turn stable polymer powders into sticky messes or trigger pre-degradation, killing shelf life. Labeling, too, helps clinicians and scientists avoid mix-ups, pointing out lot numbers, expiration, recommended storage, and guidance for reconstituting powders or melting pellets into new shapes.
Making RG 503 H involves simple ingredients but tricky choreography. It starts with ring-opening polymerization of D,L-lactide and glycolide in the right proportions, often under heat and without solvents, to keep impurities away. Catalysts—frequently tin octoate—spark the reaction, but the challenge comes after: the mixture cools, purification strips away unused acid or leftover catalyst, and what’s left is vacuum-dried to remove even trace moisture. Labs that cut corners here see quality drop fast. Getting the D,L-lactide ratio correct means tuning the polymer’s properties every time; in practice, chemists run small test batches, probing viscosity and solubility with each tweak. For end-products such as drug carriers or tissue scaffolds, further processing steps—like spray-drying into microparticles, extrusion into rods, or molding into sheets—bring precise control for each medical application.
Living with polymers rarely means leaving them untouched. Scientists modify RG 503 H to fit evolving medical needs: attaching drug molecules, grafting bioactive peptides, or tweaking surface chemistry to control how fast water seeps in and triggers breakdown. That’s not just chemistry for fun—surface modifications stop certain immune reactions or speed up healing in difficult cases, like diabetic ulcers. People working with the polymer sometimes blend it with other biodegradable materials like polycaprolactone or natural proteins, controlling how soon a device disappears or which cell types colonize it first. Conjugation of fluorescent markers helps track the material inside animal models, giving researchers real-time feedback. These advances rarely make headlines outside science, but improvements in chemical flexibility quietly boost the reliability and safety of next-generation implants and slow-release medicines.
It can get confusing out there: the same polymer emerges under many names. Resomer RG 503 H signals a certain blend of lactic to glycolic acid, but journals and product boxes also refer to PLGA, Resomer, or simply polylactide-co-glycolide. Keeping terminology straight matters outside academia; an incorrect selection in clinical trials, for example, disrupts results, slows research, or, worse, puts patients at risk. Commercial and generic names often overlap in literature searches, which slows down regulatory review and patent filing. Those new to the field can learn fast—mix up Resomer RG 503 H and its higher molecular weight cousins, and the physical breakdown rates won’t match patient needs or scientific goals.
Handling RG 503 H in the factory or lab doesn’t call for full hazmat gear, but strict cleanliness and quality assurance run the show. Operators suit up with gloves, masks, and controlled access—not because the powder jumps out of the bag at you, but because trace contaminants or fingerprints can derail a batch. Regulatory agencies audit storage temperature and humidity because even short lapses allow the copolymer to start breaking down early. Waste streams and spills can’t just go down the drain; any residual monomer or degradation product joins hazardous waste queues, protecting waterways and staff. In my own experience, most complications come not from acute toxicity but from poor housekeeping: left too long exposed to air, or mishandled during blending, and you have wasted money and raw materials. Training and routine follow-ups with staff never go out of style.
Medicine would look very different if RG 503 H hadn’t caught on. Most universities tell students about its role in drug-delivery microcapsules—tiny spheres that hold chemotherapy, anti-inflammatories, or antibiotics, releasing them in steady doses over days or weeks. Dentists and orthopedic surgeons rely on implants formed from this polymer: screws, pins, and plates that hold bone but quietly break down as new tissue forms, saving patients from long, painful second surgeries. Even vaccine developers lean on these microparticles to train the immune system with controlled bursts of viral proteins, improving response in tricky diseases. Labs across the world use RG 503 H in experimental cell scaffolds, growing new cartilage or skin where injuries once demanded amputation or left lifelong scars. Tools like wound dressings, tissue regeneration matrices, and suture anchors round out its contributions. At this point, RG 503 H is more than a single-use product; it’s an enabler of surgeries, therapies, and recovery paths that simply didn’t exist for earlier generations.
The search for better biomaterials never lets up, and RG 503 H stays at the center of that race. Young scientists use it as a teaching material—its known safety and predictable behavior build foundations for more daring experiments. In the push for precision medicine, research pivots around custom-shaped RG 503 H scaffolds for nerve and cardiac repair, hoping to offer personalized options where off-the-shelf devices fail. Labs compete to load it with mRNA or genetic payloads for vaccines, nudging immune cells to fight cancer or chronic infections. Longer-term, the challenge remains guiding the body’s own repairs: getting stem cells or growth factors to thrive inside polymer frameworks and then having the RG 503 H disappear as natural tissue takes over. From my perspective, these efforts show both the maturing and restless side of the field. While RG 503 H no longer excites like a brand-new discovery, it offers a proven platform where hundreds of incremental improvements compound into real therapeutic gains.
Sometimes, enthusiasm for “biodegradable” materials goes unchecked, but years of animal trials and patient experience keep RG 503 H grounded. The polymer breaks down into lactic and glycolic acid, both metabolized and cleared through natural pathways. Large-scale toxicity reviews from regulatory agencies flag very few complications, and those that arise often link to surgical technique or improper sterilization, not the polymer itself. There’s value in systematic toxicity studies, though: rare reactions like localized inflammation or, less commonly, allergic responses, highlight gaps in purity or batch consistency rather than any deep-seated risk. The field hasn’t stopped watching—every new application draws new rounds of scrutiny. For high-risk uses like nerve regeneration or pediatric implants, the bar moves even higher; ongoing research checks for subtle effects on developing tissues and long-term immune system activation. Evidence so far keeps RG 503 H on lists of safe, reliable materials, even as investigations stretch into chronic exposure and combination therapies.
Looking ahead, the challenge isn’t making RG 503 H safer—current science has handled most obvious risks—but pushing its boundaries for both new therapies and sustainability. Demand rises for “smarter” polymers that respond to the body’s signals: breaking down faster in inflamed tissue or sticking around where healing drags on. Environmental pressure to cut plastic waste even in the clinic drives interest in recovery or recycling of used implant materials, a hurdle few have cracked. Digital tools map out more complex blends, simulating microstructure and predicting behavior before any human or animal test, speeding up discovery cycles. On the business end, global inequalities in access mean that while advanced hospitals import RG 503 H devices for routine surgeries, clinics in many countries only read about them. Bridging that gap—through cost-cutting production, regulatory harmonization, or open-source design—could amplify the next leap in patient care and research. If history holds, the quiet advances made with RG 503 H won’t just stay in the OR: they’ll seep into sports injuries, chronic disease management, and regenerative medicine, guiding care well beyond what textbooks of my youth imagined.
I have spent years talking with researchers and pharmacists who see Poly(D,L-lactide-co-glycolide), known in many labs as Resomer RG 503 H, everywhere in medical technology. Ask anyone who has worked in drug delivery or surgery about advances they find promising, and you are likely to hear something about biodegradable polymers. These aren’t just technical terms tossed around in science journals—they touch real lives.
Resomer RG 503 H stands out partly because it disappears in the body over time. That may sound simple, but it changes everything for people relying on sustained-release medications or needing a suture that won’t stick around forever. Designed for controlled drug release, this co-polymer earns its keep by breaking down into lactic and glycolic acids, which the body ultimately turns into carbon dioxide and water. Our bodies know how to handle these materials because they’re already familiar chemicals in our metabolism.
People sometimes ask, “Why not just take a pill?” For anyone fighting cancer, infections, or chronic conditions, taking a pill doesn’t always solve the problem; certain drugs work better when released slowly where they’re needed most. That’s where Resomer RG 503 H shines. Imagine a tiny capsule injected right at a cancer site, quietly delivering chemotherapy without hammering the rest of the body. Poly(D,L-lactide-co-glycolide) holds onto the drug, letting it go in steady doses as the polymer itself dissolves. Paclitaxel, leuprolide, risperidone—these big-name medications have all benefited from being packed in this kind of delivery system.
According to several FDA clearances and clinical papers, these biodegradable carriers have brought down infection rates from unnecessarily lingering implants and reduced severe side effects by keeping medicine right where it’s needed. Patients see fewer needle sticks and less time in hospitals. Less stress, less pain, better outcomes.
Doctors used to rely on metal pins or non-absorbable sutures—often leading to a dreaded second surgery just to get the hardware out. As a parent, the last thing I’d want for my child after a broken arm would be another round with a scalpel. Polymers like Resomer RG 503 H solve this. Surgeons can use pins, screws, or fixation plates made from this material, knowing the body will absorb it naturally once the bone heals. The days of “removal day” are fading away in many clinics.
With the rise in environmental awareness, more researchers look for greener options in healthcare. Synthetic biodegradables like Resomer RG 503 H often beat petroleum-based plastics, especially when you consider medical waste pile-up. Factories must follow strict purity standards for medical-grade PLA/PGA blends, and that’s not just about safety. Tiny amounts of contamination can affect how a device performs or how quickly a drug comes out. This means real discipline on the production floor, sharp eyes during quality checks, and regular audits from watchdog agencies like the FDA and EMA.
As new therapies push into the market—from gene therapies to regenerative medicine—there’s more weight on materials that interact safely with living tissue. Ongoing studies explore finer control by tweaking how Resomer RG 503 H breaks down, chasing longer or shorter release times. There’s plenty of heavy lifting left for companies working on scale, cost, and QA, but the trajectory points to even more options for patients who can’t wait for the next leap in care.
Every scientist handling biodegradable polymers knows that molecular weight shapes how a material dissolves, degrades, and performs in real world applications. Resomer RG 503 H remains a common name in labs and factories working on drug delivery, especially for controlled release techniques. The label “RG 503 H” signals a poly(lactic-co-glycolic acid), or PLGA, carrying an average molecular weight in the area of 24,000 to 38,000 Daltons. More specifically, most technical data sheets point at a sweet spot near 34,000 Daltons for this grade.
During my years working on microencapsulation projects, only polymers with well-characterized features performed as expected. A batch of RG 503 H can shift a drug’s release profile from slow and steady to fast and erratic, all traced back to the chain length—the defining factor for molecular weight. Drug companies lean on this number because it ties directly to how quickly the final microparticles or implants break down in the body.
If the chains run short, they break apart and dissolve in days or weeks. Go too high, and the body spends months, even years, chipping away at the mass. Knowing the molecular weight avoids batch failures, which can wipe out patient outcomes and years of research. When scientists ask about molecular weight, it’s more than technical curiosity—they are guarding predictability in both lab work and eventual patient use.
Supplying pharmaceutical-grade polymers demands tight quality control. Resomer RG 503 H’s molecular weight lands between 24,000 and 38,000 Daltons, measured through gel permeation chromatography—an industry standard with a well-documented validation trail. Suppliers issue every batch with a certificate spelling out both the number-average and weight-average molecular weights, not just to reassure researchers, but also to help pass regulatory audits.
The lack of terminal ester groups—signaled by the “H” for “acid end-capped”—also matters. No end caps mean more reactive terminal carboxyl groups, which can alter the degradation rate and even influence how drugs bind or release over time. These chemical tweaks are not marketing—clinical trial reproducibility depends on these molecular details lining up every single time.
Researchers keep asking for tighter molecular weight distributions, not only an average number. That’s because wide variations inside a single batch can derail delicate drug loading or encapsulation steps. More suppliers have started providing ranges and not just averages, but the field still needs even more transparent quality reports. Greater detail means less guesswork, safer clinical translation, and faster troubleshooting in the event of instability or failure.
On the regulatory side, authorities such as the U.S. FDA or EMA examine every data sheet for these polymers. They expect clear, justified molecular weight claims, and supporting documentation on testing methods. Some firms now include side-by-side GPC chromatograms with shipments, not only summary stats. That trend reflects a push toward greater transparency and traceability for every synthesize-and-ship cycle.
Experienced researchers won’t settle for vague or poorly documented data on material properties. For Resomer RG 503 H, the reliable reference for molecular weight remains in the upper twenties to thirties in the kiloDalton range, centered near 34,000. This core detail stands as the foundation for making trustworthy formulations, ensuring safety, and helping new therapies reach patients with less risk and more confidence.
Pharmaceutical researchers love materials that work well with the body and break down cleanly after serving their purpose. Poly(lactide-co-glycolide), or PLGA, gets a lot of attention for these traits. Resomer RG 503 H, a specific PLGA, pops up in countless research papers and actual products. It comes as a copolymer of lactic and glycolic acid, with a 50:50 ratio and a molecular weight in the mid-range. You’ll encounter this stuff in all sorts of drug delivery devices and even in surgical sutures, so the conversation about its safety and breakdown really matters.
Whenever you bring a synthetic material into contact with living tissue, there’s a risk. Will the material trigger immune rejection? Will it stick around, clog things up, or cause complications? My own work in the lab always circles back to these choices. Easy integration with biological systems — biocompatibility — is no small ask. On top of that, materials like Resomer RG 503 H need to safely biodegrade into harmless molecules once their job is done.
Resomer RG 503 H delivers both. Studies show this polymer breaks down inside the body into lactic and glycolic acids. Your body handles these breakdown products naturally, converting them to CO2 and water, which you breathe out or pass off through normal metabolism. Hospitals have been relying on PLGA-based devices for years, so the track record brings plenty of peace of mind. Examples include long-acting injectable drugs, microcapsules, and dissolvable stitches. The FDA has cleared dozens of products built with this polymer.
Lab studies and patient reports paint a consistent picture. Resomer RG 503 H goes about its business and then clears out, leaving minimal trace behind. Adverse reactions link more strongly to other ingredients, such as drug payloads or manufacturing residues, than to the polymer itself. Researchers like me see strong cell survival and low inflammation in tissue experiments. Peer-reviewed research backs up these claims — look up journals like Biomaterials and Advanced Drug Delivery Reviews. There’s real transparency in the data and review process, so trust builds naturally over time.
Not every project is sunshine and smooth sailing. Even highly-regarded materials have limitations. One thing I’ve noticed: the breakdown rate depends heavily on polymer composition, particle size, and local conditions. Rapid degradation releases acid into the surrounding area, which could cause swelling or localized irritation. Handy in short-term applications, but not always welcome for longer use. Careless formulation or poor-quality controls open the door to micro-contaminants, which could trigger inflammation. As a field, we can’t afford to get lazy with purity checks or batch-to-batch consistency.
Sustainable disposal and environmental fate warrant a look, too. Biodegradable inside the body doesn’t always mean harmless outside of it. Hospitals and manufacturers need clear protocols for waste handling, and policymakers should keep an eye on lifecycle management.
Industry and academia keep close tabs on new data as it comes out. Manufacturers should commit to rigorous purification and reliable quality control during production. Product developers need to match the polymer grade, molecular weight, and device format to patient needs. Researchers drive progress by sharing findings — both positive and critical — to keep the bar high. Regulators must stay up-to-date, reviewing new formulations in light of the latest safety and biodegradation studies.
Biodegradable, biocompatible polymers like Resomer RG 503 H open doors to innovative treatments. The science supports its safety for most intended uses, but responsible stewardship, clear communication, and quality assurance will keep its legacy positive — in the lab, clinic, and beyond.
Anyone who’s spent time working with advanced polymers—like Resomer RG 503 H—knows how much small things matter. You can’t just leave the container on a shelf and expect consistent results later. This is a material with a serious job in medicine, serving as a biodegradable backbone for drug delivery systems. Keeping it stable means less waste, reliable performance, and above all, safer outcomes for patients.
One of the biggest factors that impacts the stability of Resomer RG 503 H boils down to temperature. I once saw an entire batch go off-spec because someone thought a stockroom in the back would “probably be cool enough.” The golden rule: keep Resomer RG 503 H below 25°C, ideally as close to standard refrigeration—around 2°C to 8°C—as possible. Long-term exposure to higher temperatures speeds up hydrolysis. That’s a fancy way of saying the polymer chains start breaking down, and nobody wants their product to degrade before it even sees a test tube.
Cold environments help slow that reaction. A dedicated fridge that stays clean and dry beats any warehouse or storeroom shelf in the long run. It’s not about being precious—it’s just about understanding how sensitive these materials get if left to their own devices. In real-life labs, overlooked refrigeration leads to failed tests, wasted money, and frustrated teams stuck sorting out which batch went bad.
Humidity creeps up faster than people expect. Moisture in the air looks innocent, but for Resomer RG 503 H, it spells trouble even at a molecular level. High humidity kicks the hydrolysis reaction into high gear, slicing apart those helpful chains. Folks relying on air conditioners to manage moisture sometimes get a nasty surprise. You want low humidity and sealed containers with desiccants—like silica gel packs—inside. Anytime I've shipped or stored these materials, a sealed amber bottle with a silica pack inside sits at the top of the checklist. Opening the bottle for longer than needed guarantees extra exposure, so get what’s needed and then close that cap tightly again.
Sunshine feels good, but it wreaks havoc on sensitive polymers. Direct light—especially anything with ultraviolet radiation—can shift the chemical structure. I’ve heard horror stories about students leaving samples by sunny windows, only to discover a sticky mess instead of the pristine powder they expected. Stick with amber bottles or opaque containers, and always store them in the dark.
An important practice: put clear, durable labels with the date of receipt, and keep a sharp eye on expiration dates. Even with tip-top storage, polymers like Resomer RG 503 H lose quality over time. It's not just paperwork; tracking dates means catching any downward trends or batch issues before mistakes move further into the process.
For labs that really care about results, dedicated refrigerators with temperature logs, regular audits of storage areas, and tightly controlled humidity stand out as solid investments. Small-scale users sometimes skip steps, thinking it won’t matter, but these habits quickly pay off in peace of mind and less scrambling when things go wrong. If storing for more than a few weeks, divide the powder into single-use bottles to avoid repeated exposure. Don’t overlook staff training—everyone who handles the product should know these routines, because one slipup can ruin a batch and cost serious time and money.
Paying attention to cold, dry, and dark storage—combined with airtight packaging—keeps Resomer RG 503 H dependable from the first gram down to the last. Getting this right doesn’t just tick a box. In my experience, it builds trust in the materials and lets innovators focus on discovery instead of troubleshooting avoidable mistakes.
Walk into any hospital and you’ll notice how technology shapes care. Among the many behind-the-scenes players, Resomer RG 503 H turns up in some critical applications. This biodegradable polymer—made of poly(lactide-co-glycolide)—doesn’t show up on medicine bottles or advertisements, but it does heavy lifting in drug delivery systems. I remember sitting in a research lab, watching teams debate the best way to get precise doses of medicine into the body. Many chose Resomer RG 503 H because it breaks down at a predictable rate, gently releasing medication over days or weeks. This makes a huge difference for people dealing with chronic pain or cancer, since it means fewer hospital visits for repeat injections.
Resomer RG 503 H isn’t just about pills and capsules. Surgeons use devices that dissolve safely without another surgery to remove them. The trust comes from its long record—approved by regulatory agencies in the U.S., Europe, and Asia for certain uses. Orthopedic pins, screws, and even tiny stents often use this polymer. A fellow grad student once showed me how simple fractures can get better support with RG 503 H-based implants. The patient gets support where bone healing happens, then the device fades away, leaving natural tissue. It always struck me how this approach reduces pain, risk of infection, and even costs, since you skip an extra operation.
Vaccines remain a cornerstone of public health, but storage and timing can sabotage results. I’ve seen research teams use Resomer RG 503 H to make vaccine microspheres. They can carry delicate molecules that trigger immune responses and release them right when needed. During a recent flu season, my cousin joined a trial for a long-acting COVID booster that used this trick. He got one shot, and RG 503 H took care of the timing. In remote clinics where returning isn’t easy, long-release vaccines can protect people who otherwise miss yearly boosters. No scientist does this for show; it solves a real challenge for at-risk patients everywhere.
Researchers rely on Resomer RG 503 H in prototype devices and advanced studies. The granular powder dissolves in certain solvents, turning into a smooth paste or coating that surrounds sensitive drugs. Its low acid content helps sensitive biologicals stay stable. As a grad student working with antibiotics, I watched how stable these systems kept our experimental drugs, even after weeks in hectic incubators. This isn’t just a win for shelf life—patients facing infections from joint replacements or heart valves get more reliable, longer-lasting protection.
People gravitate towards what works, and Resomer RG 503 H keeps gaining fans among doctors and patients alike. Its established reputation raises trust. This trust matters even more as new drugs and treatments call for smarter carriers and biodegradable scaffolds. Going forward, wider public education about these materials could help raise confidence and speed up access to next-generation therapies, letting patients spend less time worrying and more time recovering.
| Names | |
| Preferred IUPAC name | poly[(2-hydroxypropanoic acid)-co-(hydroxyacetic acid)] |
| Other names |
DL-PLGA DL-Poly(lactide-co-glycolide) Poly(DL-lactide-co-glycolide) Poly(DL-lactic-co-glycolic acid) PLGA 50:50 Resomer RG 503 H |
| Pronunciation | /ˈpɒli di ɛl ˈlæktɪd koʊ ɡlaɪˈkɒlɪd rɪˈzəʊmər ɑːr dʒi faɪv oʊ θri eɪtʃ/ |
| Identifiers | |
| CAS Number | 26780-50-7 |
| Beilstein Reference | 4136051 |
| ChEBI | CHEBI:53497 |
| ChEMBL | CHEMBL1748505 |
| ChemSpider | 4536081 |
| DrugBank | DB15640 |
| ECHA InfoCard | 03b630af-b589-336b-ab6e-5774fc15e413 |
| Gmelin Reference | B05878 |
| MeSH | Dioxanes |
| PubChem CID | 25088107 |
| RTECS number | RR0350000 |
| UNII | 3X8G1787AK |
| UN number | Not regulated |
| CompTox Dashboard (EPA) | DTXSID8070857 |
| Properties | |
| Chemical formula | (C₃H₄O₂)_x(C₂H₂O₂)_y |
| Molar mass | 30000–60000 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.19 g/cm³ |
| Solubility in water | insoluble |
| log P | 2.15 |
| Acidity (pKa) | 3.08 (Predict pKa) |
| Basicity (pKb) | 7.9 |
| Magnetic susceptibility (χ) | -9.6e-6 |
| Refractive index (nD) | 1.47 |
| Viscosity | 0.32–0.44 dL/g |
| Dipole moment | 2.78 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -748.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3534.8 kJ/mol |
| Pharmacology | |
| ATC code | V07AX |
| Hazards | |
| Main hazards | May cause respiratory irritation. May cause eye irritation. May cause skin irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Wash thoroughly after handling. Wear protective gloves/eye protection/face protection. IF ON SKIN: Wash with plenty of water. If skin irritation occurs: Get medical advice/attention. Take off contaminated clothing and wash it before reuse. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Autoignition temperature | 400 °C |
| LD50 (median dose) | > 5,000 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.5–5 mg/mL |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Poly(lactic acid) Polyglycolide Poly(lactic-co-glycolic acid) Polyglycolic acid Resomer RG 502 H Resomer RG 504 H Polycaprolactone |
